413 related articles for article (PubMed ID: 8630236)
1. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
[TBL] [Abstract][Full Text] [Related]
3. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
4. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
5. Finasteride in the treatment of benign prostatic hyperplasia.
Ekman P; Andersen JT; Wolf H
Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
[TBL] [Abstract][Full Text] [Related]
6. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
[TBL] [Abstract][Full Text] [Related]
8. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
9. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
10. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
11. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
Granados Loarca EA
Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
14. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
15. [Finasteride (Proscar) for benign prostatic hypertrophy].
Matzkin H; Chen J; Braf Z
Harefuah; 1993 Dec; 125(12):453-6, 496. PubMed ID: 7509305
[TBL] [Abstract][Full Text] [Related]
16. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
[TBL] [Abstract][Full Text] [Related]
17. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
Djavan B; McConnell J
Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of men on finasteride.
Gormley GJ
Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]